{"transactions":[{"id":901176,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":66220,"kind":"person","name":"Stephenson Pamela","position":1,"cik":"0001767650","reported_name":"Stephenson Pamela","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-02-18T02:15:38.000Z","date":"2026-02-17","kind":"sale","planned":false,"acquired":false,"shares":5531,"price":62.86,"value":347678.66,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of certain restricted stock units previously reported in Table I. This sale is a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."}],"balance_after":80998,"source":{"system":"sec-edgar","filing":"0001193125-26-055646","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816736/000119312526055646/ownership.xml","form_type":"4"}},{"id":910071,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":66220,"kind":"person","name":"Stephenson Pamela","position":1,"cik":"0001767650","reported_name":"Stephenson Pamela","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-12T00:46:22.000Z","date":"2026-02-10","kind":"grant","planned":false,"acquired":true,"shares":25500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying this option vest in 48 equal monthly installments commencing on March 10, 2026, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":25500,"derivative":{"exercise_price":74.75,"expiration_date":"2036-02-09","underlying":"Common Stock","underlying_shares":25500},"source":{"system":"sec-edgar","filing":"0001193125-26-047198","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1816736/000119312526047198/ownership.xml","form_type":"4"}},{"id":910070,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":66220,"kind":"person","name":"Stephenson Pamela","position":1,"cik":"0001767650","reported_name":"Stephenson Pamela","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-02-12T00:46:22.000Z","date":"2026-02-10","kind":"grant","planned":false,"acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\"), each representing a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest annually in four 25% installments commencing on February 15, 2027, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":86529,"source":{"system":"sec-edgar","filing":"0001193125-26-047198","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816736/000119312526047198/ownership.xml","form_type":"4"}},{"id":1255986,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":66220,"kind":"person","name":"Stephenson Pamela","position":1,"cik":"0001767650","reported_name":"Stephenson Pamela","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-02-21T00:38:55.000Z","date":"2025-02-18","kind":"sale","planned":false,"acquired":false,"shares":3137,"price":54.58,"value":171217.46,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of certain restricted stock units granted on February 26, 2024 and previously reported in Table I. This sale is a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."}],"balance_after":69529,"source":{"system":"sec-edgar","filing":"0000950170-25-024477","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816736/000095017025024477/ownership.xml","form_type":"4"}},{"id":1271851,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":66220,"kind":"person","name":"Stephenson Pamela","position":1,"cik":"0001767650","reported_name":"Stephenson Pamela","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-12T23:48:30.000Z","date":"2025-02-10","kind":"grant","planned":false,"acquired":true,"shares":36000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying this option vest in 48 equal monthly installments commencing on March 10, 2025, subject to the Reporting Person's continuted service on each such vesting date."}],"balance_after":36000,"derivative":{"exercise_price":54.71,"expiration_date":"2035-02-09","underlying":"Common Stock","underlying_shares":36000},"source":{"system":"sec-edgar","filing":"0000950170-25-019106","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1816736/000095017025019106/ownership.xml","form_type":"4"}},{"id":1271850,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":66220,"kind":"person","name":"Stephenson Pamela","position":1,"cik":"0001767650","reported_name":"Stephenson Pamela","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-02-12T23:48:30.000Z","date":"2025-02-10","kind":"grant","planned":false,"acquired":true,"shares":36000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\"), each representing a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest annually in four 25% installments commencing on February 15, 2026, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":72666,"source":{"system":"sec-edgar","filing":"0000950170-25-019106","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816736/000095017025019106/ownership.xml","form_type":"4"}},{"id":1616139,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":66220,"kind":"person","name":"Stephenson Pamela","position":1,"cik":"0001767650","reported_name":"Stephenson Pamela","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-27T22:38:25.000Z","date":"2024-02-26","kind":"grant","planned":false,"acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying this option shall vest and become exercisable on February 26, 2025, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":55000,"derivative":{"exercise_price":64.66,"expiration_date":"2034-02-25","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0000950170-24-021448","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1816736/000095017024021448/ownership.xml","form_type":"4"}},{"id":1616138,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":66220,"kind":"person","name":"Stephenson Pamela","position":1,"cik":"0001767650","reported_name":"Stephenson Pamela","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-02-27T22:38:25.000Z","date":"2024-02-26","kind":"grant","planned":false,"acquired":true,"shares":36666,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":36666,"source":{"system":"sec-edgar","filing":"0000950170-24-021448","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816736/000095017024021448/ownership.xml","form_type":"4"}},{"id":1761647,"issuer":{"id":109058,"kind":"organization","name":"Zynerba Pharmaceuticals, Inc.","symbol":"ZYNE"},"owners":[{"id":66220,"kind":"person","name":"Stephenson Pamela","position":1,"cik":"0001767650","reported_name":"Stephenson Pamela","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-10-11T10:12:57.000Z","date":"2023-10-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":71736,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per Share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per Share exercise price of such option and (ii) one CVR. (continued in footnote 5)"},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"(Continued from footnote 4) Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per Share exercise price greater than or equal to the Cash Amount, and less than $2.71, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, minus the per Share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per Share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per Share exercise price of such option and (ii) one CVR. (continued in footnote 5)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"(Continued from footnote 4) Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per Share exercise price greater than or equal to the Cash Amount, and less than $2.71, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, minus the per Share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment."}],"balance_after":0,"derivative":{"exercise_price":0.3501,"expiration_date":"2033-06-13","underlying":"Common Stock","underlying_shares":71736},"source":{"system":"sec-edgar","filing":"0001140361-23-047743","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1621443/000114036123047743/form4.xml","form_type":"4"}},{"id":1761646,"issuer":{"id":109058,"kind":"organization","name":"Zynerba Pharmaceuticals, Inc.","symbol":"ZYNE"},"owners":[{"id":66220,"kind":"person","name":"Stephenson Pamela","position":1,"cik":"0001767650","reported_name":"Stephenson Pamela","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-10-11T10:12:57.000Z","date":"2023-10-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":34663,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per Share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per Share exercise price of such option and (ii) one CVR. (continued in footnote 5)"},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"(Continued from footnote 4) Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per Share exercise price greater than or equal to the Cash Amount, and less than $2.71, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, minus the per Share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per Share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per Share exercise price of such option and (ii) one CVR. (continued in footnote 5)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"(Continued from footnote 4) Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per Share exercise price greater than or equal to the Cash Amount, and less than $2.71, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, minus the per Share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment."}],"balance_after":0,"derivative":{"exercise_price":1.01,"expiration_date":"2032-06-14","underlying":"Common Stock","underlying_shares":34663},"source":{"system":"sec-edgar","filing":"0001140361-23-047743","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1621443/000114036123047743/form4.xml","form_type":"4"}},{"id":1761645,"issuer":{"id":109058,"kind":"organization","name":"Zynerba Pharmaceuticals, Inc.","symbol":"ZYNE"},"owners":[{"id":66220,"kind":"person","name":"Stephenson Pamela","position":1,"cik":"0001767650","reported_name":"Stephenson Pamela","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-10-11T10:12:57.000Z","date":"2023-10-10","kind":"other","planned":false,"acquired":false,"shares":47824,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"This line item represents unvested restricted stock awards (\"RSAs\") held by the Reporting Person that were tendered pursuant to the Offer. Pursuant to the terms of the Merger Agreement, at the Effective Time, each unvested RSA that was outstanding immediately prior to the Effective Time and not validly tendered in the Offer was cancelled and converted into the right to receive the Merger Consideration, subject to withholding of applicable taxes and without interest."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This line item represents unvested restricted stock awards (\"RSAs\") held by the Reporting Person that were tendered pursuant to the Offer. Pursuant to the terms of the Merger Agreement, at the Effective Time, each unvested RSA that was outstanding immediately prior to the Effective Time and not validly tendered in the Offer was cancelled and converted into the right to receive the Merger Consideration, subject to withholding of applicable taxes and without interest."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001140361-23-047743","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1621443/000114036123047743/form4.xml","form_type":"4"}},{"id":1761644,"issuer":{"id":109058,"kind":"organization","name":"Zynerba Pharmaceuticals, Inc.","symbol":"ZYNE"},"owners":[{"id":66220,"kind":"person","name":"Stephenson Pamela","position":1,"cik":"0001767650","reported_name":"Stephenson Pamela","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-10-11T10:12:57.000Z","date":"2023-10-10","kind":"other","planned":false,"acquired":false,"shares":27954,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of that certain Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of August 14, 2023, by and among the Issuer, Harmony Biosciences Holdings, Inc., a Delaware corporation (\"Parent\") and Xylophone Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), Merger Sub completed a tender offer (the \"Offer\") for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, effective as of October 10, 2023 (the \"Effective Time\" with the Issuer surviving the merger). (continued in footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from footnote 1) At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (a) $1.1059 per Share (the \"Cash Amount\") in cash, subject to any applicable withholding taxes and without interest, plus (b) one contingent value right (each, a \"CVR\") per Share (the \"CVR Amount\" and together with the Cash Amount, the \"Merger Consideration\"), which represents the right to receive up to approximately $2.5444 per Share in the form of one or more potential contingent payments, in cash, subject to any applicable withholding taxes and without interest, upon the achievement of certain milestones (such applicable payment, each, a \"Milestone Payment\")."}],"balance_after":47824,"source":{"system":"sec-edgar","filing":"0001140361-23-047743","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1621443/000114036123047743/form4.xml","form_type":"4"}},{"id":1853795,"issuer":{"id":109058,"kind":"organization","name":"Zynerba Pharmaceuticals, Inc.","symbol":"ZYNE"},"owners":[{"id":66220,"kind":"person","name":"Stephenson Pamela","position":1,"cik":"0001767650","reported_name":"Stephenson Pamela","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-15T16:30:21.000Z","date":"2023-06-13","kind":"grant","planned":false,"acquired":true,"shares":71736,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests in full upon the earlier of (i) June 13, 2024 or (ii) the day before the Company's 2024 annual meeting of stockholders."}],"balance_after":71736,"derivative":{"exercise_price":0.3501,"expiration_date":"2033-06-13","underlying":"Common Stock","underlying_shares":71736},"source":{"system":"sec-edgar","filing":"0001062993-23-013668","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1621443/000106299323013668/form4.xml","form_type":"4"}},{"id":1853794,"issuer":{"id":109058,"kind":"organization","name":"Zynerba Pharmaceuticals, Inc.","symbol":"ZYNE"},"owners":[{"id":66220,"kind":"person","name":"Stephenson Pamela","position":1,"cik":"0001767650","reported_name":"Stephenson Pamela","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-15T16:30:21.000Z","date":"2023-06-14","kind":"sale","planned":false,"acquired":false,"shares":115,"price":0.3481,"value":40.0315,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"This transaction represents shares required to be sold by the Reporting Person to satisfy certain equity plan administrator fees and taxes in connection with the vesting of shares of restricted stock. This sale was mandated by the equity plan administrator and does not represent a discretionary trade by the Reporting Person."}],"balance_after":75778,"source":{"system":"sec-edgar","filing":"0001062993-23-013668","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1621443/000106299323013668/form4.xml","form_type":"4"}},{"id":1853793,"issuer":{"id":109058,"kind":"organization","name":"Zynerba Pharmaceuticals, Inc.","symbol":"ZYNE"},"owners":[{"id":66220,"kind":"person","name":"Stephenson Pamela","position":1,"cik":"0001767650","reported_name":"Stephenson Pamela","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-15T16:30:21.000Z","date":"2023-06-13","kind":"grant","planned":false,"acquired":true,"shares":47824,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock award vests in full upon the earlier of (i) June 13, 2024 or (ii) the day before the Company's 2024 annual meeting of stockholders."}],"balance_after":75893,"source":{"system":"sec-edgar","filing":"0001062993-23-013668","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1621443/000106299323013668/form4.xml","form_type":"4"}},{"id":1978953,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":66220,"kind":"person","name":"Stephenson Pamela","position":1,"cik":"0001767650","reported_name":"Stephenson Pamela","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2023-03-02T16:54:55.000Z","date":"2023-03-02","kind":"disposition_to_issuer","acquired":false,"shares":75513,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each restricted stock unit represents a contingent right to receive one Share."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Merger Agreement, (a) each outstanding restricted stock unit (each, a \"Company RSU\") that was granted prior to the date of the Merger Agreement, and each Company RSU that was granted on or after the date of the Merger Agreement and that is designated in the confidential disclosure schedules as an \"Accelerated 2023 RSU,\" was canceled and converted into the right to receive (1) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such Company RSU immediately prior to the Effective Time multiplied by (y) $42.00 and (2) one CVR for each Share subject to such Company RSU immediately prior to the Effective Time; and (b) each Company RSU that was granted on or after the date of the Merger Agreement and that is designated in the confidential disclosure schedules as a \"Cancelled 2023 RSU\" was canceled and had no further force or effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, (a) each outstanding restricted stock unit (each, a \"Company RSU\") that was granted prior to the date of the Merger Agreement, and each Company RSU that was granted on or after the date of the Merger Agreement and that is designated in the confidential disclosure schedules as an \"Accelerated 2023 RSU,\" was canceled and converted into the right to receive (1) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such Company RSU immediately prior to the Effective Time multiplied by (y) $42.00 and (2) one CVR for each Share subject to such Company RSU immediately prior to the Effective Time; and (b) each Company RSU that was granted on or after the date of the Merger Agreement and that is designated in the confidential disclosure schedules as a \"Cancelled 2023 RSU\" was canceled and had no further force or effect."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Not applicable."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":75513},"source":{"system":"sec-edgar","filing":"0001209191-23-014769","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919123014769/doc4.xml","form_type":"4"}},{"id":1978952,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":66220,"kind":"person","name":"Stephenson Pamela","position":1,"cik":"0001767650","reported_name":"Stephenson Pamela","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-03-02T16:54:55.000Z","date":"2023-03-02","kind":"disposition_to_issuer","acquired":false,"shares":37500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, (a) each outstanding option to purchase Shares (each, a \"Company Option\") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an \"In the Money Option\"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and (B) one CVR for each Share subject to such In the Money Option\nimmediately prior to the Effective Time; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise price per Share equal to or greater than $42.00 but less than $52.00 (each, an \"Out of the Money Option\")"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continue from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration, and had no further force or effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, (a) each outstanding option to purchase Shares (each, a \"Company Option\") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an \"In the Money Option\"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and (B) one CVR for each Share subject to such In the Money Option\nimmediately prior to the Effective Time; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise price per Share equal to or greater than $42.00 but less than $52.00 (each, an \"Out of the Money Option\")"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continue from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration, and had no further force or effect."}],"balance_after":0,"derivative":{"exercise_price":28.76,"expiration_date":"2029-03-24","underlying":"Common Stock","underlying_shares":37500},"source":{"system":"sec-edgar","filing":"0001209191-23-014769","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919123014769/doc4.xml","form_type":"4"}},{"id":1978951,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":66220,"kind":"person","name":"Stephenson Pamela","position":1,"cik":"0001767650","reported_name":"Stephenson Pamela","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-03-02T16:54:55.000Z","date":"2023-03-02","kind":"disposition_to_issuer","acquired":false,"shares":31500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, (a) each outstanding option to purchase Shares (each, a \"Company Option\") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an \"In the Money Option\"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and (B) one CVR for each Share subject to such In the Money Option\nimmediately prior to the Effective Time; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise price per Share equal to or greater than $42.00 but less than $52.00 (each, an \"Out of the Money Option\")"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continue from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration, and had no further force or effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, (a) each outstanding option to purchase Shares (each, a \"Company Option\") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an \"In the Money Option\"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and (B) one CVR for each Share subject to such In the Money Option\nimmediately prior to the Effective Time; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise price per Share equal to or greater than $42.00 but less than $52.00 (each, an \"Out of the Money Option\")"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continue from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration, and had no further force or effect."}],"balance_after":0,"derivative":{"exercise_price":24.67,"expiration_date":"2030-01-20","underlying":"Common Stock","underlying_shares":31500},"source":{"system":"sec-edgar","filing":"0001209191-23-014769","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919123014769/doc4.xml","form_type":"4"}},{"id":1978950,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":66220,"kind":"person","name":"Stephenson Pamela","position":1,"cik":"0001767650","reported_name":"Stephenson Pamela","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-03-02T16:54:55.000Z","date":"2023-03-02","kind":"disposition_to_issuer","acquired":false,"shares":23700,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, (a) each outstanding option to purchase Shares (each, a \"Company Option\") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an \"In the Money Option\"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and (B) one CVR for each Share subject to such In the Money Option\nimmediately prior to the Effective Time; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise price per Share equal to or greater than $42.00 but less than $52.00 (each, an \"Out of the Money Option\")"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continue from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration, and had no further force or effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, (a) each outstanding option to purchase Shares (each, a \"Company Option\") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an \"In the Money Option\"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and (B) one CVR for each Share subject to such In the Money Option\nimmediately prior to the Effective Time; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise price per Share equal to or greater than $42.00 but less than $52.00 (each, an \"Out of the Money Option\")"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continue from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration, and had no further force or effect."}],"balance_after":0,"derivative":{"exercise_price":34.88,"expiration_date":"2031-01-20","underlying":"Common Stock","underlying_shares":23700},"source":{"system":"sec-edgar","filing":"0001209191-23-014769","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919123014769/doc4.xml","form_type":"4"}},{"id":1978949,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":66220,"kind":"person","name":"Stephenson Pamela","position":1,"cik":"0001767650","reported_name":"Stephenson Pamela","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2023-03-02T16:54:55.000Z","date":"2023-03-02","kind":"other","acquired":false,"shares":22242,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 8, 2023, (the \"Merger\nAgreement\"), among Ipsen Biopharmaceuticals, Inc., a Delaware corporation (\"Parent\"), Anemone Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"), solely for purposes of Sections 9.5, 9.6, 9.8 and 9.11 thereof, Ipsen Pharma SAS, a French societe par actions simplifiee (\"Guarantor\"), and the Issuer, pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.01 par value per share (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\"), effective as of March 2, 2023 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was canceled and converted into the right to receive $42.00 in cash, without interest (the \"Closing Amount\")"},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) plus one non-tradeable contractual contingent value right (\"CVR\" and each CVR together with the Closing Amount, the \"Offer Price\"), which CVR represents the right to receive a contingent payment of $10.00, net to the holder in cash, without interest, upon the achievement of the milestone set forth in a certain Contingent Value Rights Agreement (the \"CVR Agreement\") on or prior to December 31, 2027 (the \"Milestone\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 8, 2023, (the \"Merger\nAgreement\"), among Ipsen Biopharmaceuticals, Inc., a Delaware corporation (\"Parent\"), Anemone Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"), solely for purposes of Sections 9.5, 9.6, 9.8 and 9.11 thereof, Ipsen Pharma SAS, a French societe par actions simplifiee (\"Guarantor\"), and the Issuer, pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.01 par value per share (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\"), effective as of March 2, 2023 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was canceled and converted into the right to receive $42.00 in cash, without interest (the \"Closing Amount\")"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) plus one non-tradeable contractual contingent value right (\"CVR\" and each CVR together with the Closing Amount, the \"Offer Price\"), which CVR represents the right to receive a contingent payment of $10.00, net to the holder in cash, without interest, upon the achievement of the milestone set forth in a certain Contingent Value Rights Agreement (the \"CVR Agreement\") on or prior to December 31, 2027 (the \"Milestone\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-23-014769","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919123014769/doc4.xml","form_type":"4"}},{"id":2043555,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":66220,"kind":"person","name":"Stephenson Pamela","position":1,"cik":"0001767650","reported_name":"Stephenson Pamela","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2023-01-27T17:23:52.000Z","date":"2023-01-19","kind":"grant","acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of restricted stock units (\"RSUs\"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest as to 25% of the shares on January 19, 2024, 6.25% of the shares every three months thereafter beginning on April 19, 2024 and ending on January 19, 2025, and 12.5% of the shares every three months thereafter beginning on April 19, 2025 and ending on January 19, 2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents 22,242 shares of common stock and 75,513 restricted stock units."}],"balance_after":97755,"source":{"system":"sec-edgar","filing":"0001209191-23-005332","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919123005332/doc4a.xml","form_type":"4/A","original_submission_date":"2023-01-25"}},{"id":2046263,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":66220,"kind":"person","name":"Stephenson Pamela","position":1,"cik":"0001767650","reported_name":"Stephenson Pamela","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2023-01-25T20:07:54.000Z","date":"2023-01-19","kind":"grant","acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of restricted stock units (\"RSUs\"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest as to 25% of the shares on January 19, 2024, with the remainder vesting in equal installments every three months thereafter beginning on April 19, 2024 and ending on January 19, 2027."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents 22,242 shares of common stock and 75,513 restricted stock units."}],"balance_after":97755,"source":{"system":"sec-edgar","filing":"0001209191-23-004947","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919123004947/doc4.xml","form_type":"4"}},{"id":2048526,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":66220,"kind":"person","name":"Stephenson Pamela","position":1,"cik":"0001767650","reported_name":"Stephenson Pamela","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2023-01-23T17:12:56.000Z","date":"2023-01-23","kind":"sale","acquired":false,"shares":102,"price":43.8,"value":4467.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents 22,242 shares of common stock and 20,513 restricted stock units."}],"balance_after":42755,"source":{"system":"sec-edgar","filing":"0001209191-23-004459","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919123004459/doc4.xml","form_type":"4"}},{"id":2049491,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":66220,"kind":"person","name":"Stephenson Pamela","position":1,"cik":"0001767650","reported_name":"Stephenson Pamela","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2023-01-20T16:05:35.000Z","date":"2023-01-19","kind":"sale","acquired":false,"shares":1774,"price":43.9044,"value":77886.4056,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.90 to $43.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Represents 22,000 shares of common stock and 20,857 restricted stock units."}],"balance_after":42857,"source":{"system":"sec-edgar","filing":"0001209191-23-004225","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919123004225/doc4.xml","form_type":"4"}},{"id":2058560,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":66220,"kind":"person","name":"Stephenson Pamela","position":1,"cik":"0001767650","reported_name":"Stephenson Pamela","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2023-01-09T18:42:08.000Z","date":"2022-12-27","kind":"sale","acquired":false,"shares":469,"price":19.0614,"value":8939.7966,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents 18,374 shares of common stock and 26,257 restricted stock units."}],"balance_after":44631,"source":{"system":"sec-edgar","filing":"0001209191-23-002636","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919123002636/doc4a.xml","form_type":"4/A","original_submission_date":"2022-12-27"}},{"id":2058559,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":66220,"kind":"person","name":"Stephenson Pamela","position":1,"cik":"0001767650","reported_name":"Stephenson Pamela","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2023-01-09T18:41:23.000Z","date":"2022-07-22","kind":"sale","acquired":false,"shares":106,"price":24.6713,"value":2615.1578,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.67 to $24.7431, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Represents 15,923 shares of common stock and 29,726 restricted stock units."}],"balance_after":45649,"source":{"system":"sec-edgar","filing":"0001209191-23-002635","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919123002635/doc4a.xml","form_type":"4/A","original_submission_date":"2022-07-25"}},{"id":2076005,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":66220,"kind":"person","name":"Stephenson Pamela","position":1,"cik":"0001767650","reported_name":"Stephenson Pamela","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-12-27T16:05:14.000Z","date":"2022-12-27","kind":"sale","acquired":false,"shares":469,"price":19.0614,"value":8939.7966,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents 18,921 shares of common stock and 26,257 restricted stock units."}],"balance_after":45178,"source":{"system":"sec-edgar","filing":"0001209191-22-062701","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919122062701/doc4.xml","form_type":"4"}},{"id":2132236,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":66220,"kind":"person","name":"Stephenson Pamela","position":1,"cik":"0001767650","reported_name":"Stephenson Pamela","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-10-25T16:00:41.000Z","date":"2022-10-24","kind":"sale","acquired":false,"shares":104,"price":19.5764,"value":2035.9456,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents 17,828 shares of common stock and 27,819 restricted stock units."}],"balance_after":45647,"source":{"system":"sec-edgar","filing":"0001209191-22-054491","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919122054491/doc4.xml","form_type":"4"}},{"id":2150418,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":66220,"kind":"person","name":"Stephenson Pamela","position":1,"cik":"0001767650","reported_name":"Stephenson Pamela","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-09-27T16:01:35.000Z","date":"2022-09-26","kind":"sale","acquired":false,"shares":445,"price":19.4049,"value":8635.1805,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.3691 to $19.405, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Represents 17,588 shares of common stock and 28,163 restricted stock units."}],"balance_after":45751,"source":{"system":"sec-edgar","filing":"0001209191-22-051349","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919122051349/doc4.xml","form_type":"4"}},{"id":2202622,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":66220,"kind":"person","name":"Stephenson Pamela","position":1,"cik":"0001767650","reported_name":"Stephenson Pamela","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-07-25T16:14:37.000Z","date":"2022-07-22","kind":"sale","acquired":false,"shares":106,"price":24.6713,"value":2615.1578,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.67 to $24.7431, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Represents 16,470 shares of common stock and 29,726 restricted stock units. Includes 547 shares of common stock acquired under the Albireo Pharma, Inc. 2018 Employee Stock Purchase Plan (the \"ESPP\") on May 31, 2022."}],"balance_after":46196,"source":{"system":"sec-edgar","filing":"0001209191-22-043102","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919122043102/doc4.xml","form_type":"4"}},{"id":2220029,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":66220,"kind":"person","name":"Stephenson Pamela","position":1,"cik":"0001767650","reported_name":"Stephenson Pamela","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-06-28T16:02:59.000Z","date":"2022-06-27","kind":"sale","acquired":false,"shares":461,"price":19.47,"value":8975.67,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents 15,685 shares of common stock and 30,070 restricted stock units."}],"balance_after":45755,"source":{"system":"sec-edgar","filing":"0001209191-22-039597","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919122039597/doc4.xml","form_type":"4"}},{"id":2229456,"issuer":{"id":109058,"kind":"organization","name":"Zynerba Pharmaceuticals, Inc.","symbol":"ZYNE"},"owners":[{"id":66220,"kind":"person","name":"Stephenson Pamela","position":1,"cik":"0001767650","reported_name":"Stephenson Pamela","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-16T21:51:49.000Z","date":"2022-06-14","kind":"grant","acquired":true,"shares":34663,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests in full upon the earlier of (i) June 14, 2023 or (ii) the day before the Company's 2023 annual meeting of stockholders."}],"balance_after":34663,"derivative":{"exercise_price":1.01,"expiration_date":"2032-06-14","underlying":"Common Stock","underlying_shares":34663},"source":{"system":"sec-edgar","filing":"0001062993-22-015040","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1621443/000106299322015040/form4.xml","form_type":"4"}},{"id":2229455,"issuer":{"id":109058,"kind":"organization","name":"Zynerba Pharmaceuticals, Inc.","symbol":"ZYNE"},"owners":[{"id":66220,"kind":"person","name":"Stephenson Pamela","position":1,"cik":"0001767650","reported_name":"Stephenson Pamela","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-16T21:51:49.000Z","date":"2022-06-14","kind":"sale","acquired":false,"shares":40,"price":1.01,"value":40.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"This transaction represents shares required to be sold by the Reporting Person to satisfy certain equity plan administrator fees in connection with the vesting of shares of restricted stock. This sale was mandated by the equity plan administrator and does not represent a discretionary trade by the Reporting Person."}],"balance_after":28069,"source":{"system":"sec-edgar","filing":"0001062993-22-015040","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1621443/000106299322015040/form4.xml","form_type":"4"}},{"id":2229454,"issuer":{"id":109058,"kind":"organization","name":"Zynerba Pharmaceuticals, Inc.","symbol":"ZYNE"},"owners":[{"id":66220,"kind":"person","name":"Stephenson Pamela","position":1,"cik":"0001767650","reported_name":"Stephenson Pamela","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-16T21:51:49.000Z","date":"2022-06-14","kind":"grant","acquired":true,"shares":23109,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock award vests in full upon the earlier of (i) June 14, 2023 or (ii) the day before the Company's 2023 annual meeting of stockholders."}],"balance_after":28109,"source":{"system":"sec-edgar","filing":"0001062993-22-015040","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1621443/000106299322015040/form4.xml","form_type":"4"}},{"id":2291035,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":66220,"kind":"person","name":"Stephenson Pamela","position":1,"cik":"0001767650","reported_name":"Stephenson Pamela","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-04-25T16:40:29.000Z","date":"2022-04-22","kind":"sale","acquired":false,"shares":103,"price":32.9247,"value":3391.2441,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents 14,584 shares of common stock and 31,632 restricted stock units."}],"balance_after":46216,"source":{"system":"sec-edgar","filing":"0001209191-22-025524","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919122025524/doc4.xml","form_type":"4"}},{"id":2315032,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":66220,"kind":"person","name":"Stephenson Pamela","position":1,"cik":"0001767650","reported_name":"Stephenson Pamela","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-03-29T16:00:41.000Z","date":"2022-03-28","kind":"sale","acquired":false,"shares":454,"price":30.525,"value":13858.35,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"14,344 shares of common stock and 31,975 restricted stock units."}],"balance_after":46319,"source":{"system":"sec-edgar","filing":"0001209191-22-021442","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919122021442/doc4.xml","form_type":"4"}},{"id":2426478,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":66220,"kind":"person","name":"Stephenson Pamela","position":1,"cik":"0001767650","reported_name":"Stephenson Pamela","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-01-25T16:38:34.000Z","date":"2022-01-24","kind":"sale","acquired":false,"shares":416,"price":24.8822,"value":10350.9952,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.7811 to $24.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"13,235 shares of common stock and 33,538 restricted stock units."}],"balance_after":46773,"source":{"system":"sec-edgar","filing":"0001209191-22-004805","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919122004805/doc4.xml","form_type":"4"}},{"id":2430013,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":66220,"kind":"person","name":"Stephenson Pamela","position":1,"cik":"0001767650","reported_name":"Stephenson Pamela","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-01-20T16:49:36.000Z","date":"2022-01-18","kind":"grant","acquired":true,"shares":21600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of restricted stock units (\"RSUs\"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest as to 25% of the shares on January 18, 2023, with the remainder vesting in equal installments every three months thereafter beginning on April 18, 2023 and ending on January 18, 2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"12,276 shares of common stock and 34,913 restricted stock units."}],"balance_after":47189,"source":{"system":"sec-edgar","filing":"0001209191-22-004055","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919122004055/doc4.xml","form_type":"4"}},{"id":2458445,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":66220,"kind":"person","name":"Stephenson Pamela","position":1,"cik":"0001767650","reported_name":"Stephenson Pamela","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-12-27T16:02:03.000Z","date":"2021-12-27","kind":"sale","acquired":false,"shares":474,"price":23.9229,"value":11339.4546,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"12,276 shares of common stock and 13,313 restricted stock units."}],"balance_after":25589,"source":{"system":"sec-edgar","filing":"0001209191-21-071236","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919121071236/doc4.xml","form_type":"4"}},{"id":2557513,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":66220,"kind":"person","name":"Stephenson Pamela","position":1,"cik":"0001767650","reported_name":"Stephenson Pamela","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-09-28T16:32:33.000Z","date":"2021-09-27","kind":"sale","acquired":false,"shares":451,"price":32.0537,"value":14456.2187,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"11,188 shares of common stock and 14,875 restricted stock units."}],"balance_after":26063,"source":{"system":"sec-edgar","filing":"0001209191-21-057934","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919121057934/doc4.xml","form_type":"4"}},{"id":2612507,"issuer":{"id":109058,"kind":"organization","name":"Zynerba Pharmaceuticals, Inc.","symbol":"ZYNE"},"owners":[{"id":66220,"kind":"person","name":"Stephenson Pamela","position":1,"cik":"0001767650","reported_name":"Stephenson Pamela","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-08-05T17:29:56.000Z","date":"2021-08-03","kind":"grant","acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in full upon the earlier of (i) August 3, 2022, or (ii) the day before the Company's 2022 annual meeting of stockholders."}],"balance_after":7500,"derivative":{"exercise_price":4.44,"expiration_date":"2031-08-03","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001192482-21-000647","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1621443/000119248221000647/edgar.xml","form_type":"4"}},{"id":2612506,"issuer":{"id":109058,"kind":"organization","name":"Zynerba Pharmaceuticals, Inc.","symbol":"ZYNE"},"owners":[{"id":66220,"kind":"person","name":"Stephenson Pamela","position":1,"cik":"0001767650","reported_name":"Stephenson Pamela","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-08-05T17:29:56.000Z","date":"2021-08-03","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock award vests in full upon the earlier of (i) August 3, 2022, or (ii) the day before the Company's 2022 annual meeting of stockholders."}],"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001192482-21-000647","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1621443/000119248221000647/edgar.xml","form_type":"4"}},{"id":2653165,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":66220,"kind":"person","name":"Stephenson Pamela","position":1,"cik":"0001767650","reported_name":"Stephenson Pamela","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-06-28T16:02:48.000Z","date":"2021-06-25","kind":"sale","acquired":false,"shares":471,"price":36.01,"value":16960.71,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.00 to $36.29, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"10,076 shares of common stock and 16,438 restricted stock units."}],"balance_after":26514,"source":{"system":"sec-edgar","filing":"0001209191-21-043468","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919121043468/doc4.xml","form_type":"4"}},{"id":2766093,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":66220,"kind":"person","name":"Stephenson Pamela","position":1,"cik":"0001767650","reported_name":"Stephenson Pamela","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-03-31T19:21:09.000Z","date":"2021-03-29","kind":"sale","acquired":false,"shares":422,"price":34.0174,"value":14355.3428,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents 8,985 shares of common stock and 18,000 restricted stock units."}],"balance_after":26985,"source":{"system":"sec-edgar","filing":"0001209191-21-023871","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919121023871/doc4.xml","form_type":"4"}},{"id":2897456,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":66220,"kind":"person","name":"Stephenson Pamela","position":1,"cik":"0001767650","reported_name":"Stephenson Pamela","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-01-25T17:34:49.000Z","date":"2021-01-21","kind":"grant","acquired":true,"shares":23700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests as to 25% of the shares on January 21, 2022, with the remainder vesting in equal installments every three months thereafter beginning on April 21, 2022 and ending on January 21, 2025."}],"balance_after":23700,"derivative":{"exercise_price":34.88,"expiration_date":"2031-01-20","underlying":"Common Stock","underlying_shares":23700},"source":{"system":"sec-edgar","filing":"0001209191-21-005150","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919121005150/doc4.xml","form_type":"4"}},{"id":2897455,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":66220,"kind":"person","name":"Stephenson Pamela","position":1,"cik":"0001767650","reported_name":"Stephenson Pamela","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-01-25T17:34:49.000Z","date":"2021-01-21","kind":"grant","acquired":true,"shares":5500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of restricted stock units (\"RSUs\"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest as to 25% of the shares on January 21, 2022, with the remainder vesting in equal installments every three months thereafter beginning on April 21, 2022 and ending on January 21, 2025."}],"balance_after":27407,"source":{"system":"sec-edgar","filing":"0001209191-21-005150","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919121005150/doc4.xml","form_type":"4"}},{"id":2930018,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":66220,"kind":"person","name":"Stephenson Pamela","position":1,"cik":"0001767650","reported_name":"Stephenson Pamela","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2020-12-29T16:19:27.000Z","date":"2020-12-28","kind":"sale","acquired":false,"shares":460,"price":39.0742,"value":17974.132,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units."},{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents 7,844 shares of common stock and 14,063 restricted stock units."}],"balance_after":21907,"source":{"system":"sec-edgar","filing":"0001209191-20-065364","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919120065364/doc4.xml","form_type":"4"}},{"id":3022315,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":66220,"kind":"person","name":"Stephenson Pamela","position":1,"cik":"0001767650","reported_name":"Stephenson Pamela","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2020-09-25T17:05:36.000Z","date":"2020-09-25","kind":"sale","acquired":false,"shares":451,"price":33.2,"value":14973.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents 6,742 shares of common stock and 15,625 restricted stock units."}],"balance_after":22367,"source":{"system":"sec-edgar","filing":"0001209191-20-052109","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919120052109/doc4.xml","form_type":"4"}},{"id":3098324,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":66220,"kind":"person","name":"Stephenson Pamela","position":1,"cik":"0001767650","reported_name":"Stephenson Pamela","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2020-06-26T17:02:46.000Z","date":"2020-06-25","kind":"sale","acquired":false,"shares":397,"price":30.79,"value":12223.63,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to a Rule 10b5-1 arrangement to satisfy tax obligations arising out of the vesting of previously granted restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.75 to $30.85, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Represents 5,630 shares of common stock and 17,188 restricted stock units."}],"balance_after":22818,"source":{"system":"sec-edgar","filing":"0001209191-20-039107","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919120039107/doc4.xml","form_type":"4"}},{"id":3112891,"issuer":{"id":109058,"kind":"organization","name":"Zynerba Pharmaceuticals, Inc.","symbol":"ZYNE"},"owners":[{"id":66220,"kind":"person","name":"Stephenson Pamela","position":1,"cik":"0001767650","reported_name":"Stephenson Pamela","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-11T17:36:31.000Z","date":"2020-06-10","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests upon the earlier of (i) June 10, 2021 and (ii) the day before the Company's 2021 annual meeting of stockholders."}],"balance_after":15000,"derivative":{"exercise_price":5.21,"expiration_date":"2030-06-10","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001192482-20-000467","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1621443/000119248220000467/edgar.xml","form_type":"4"}},{"id":3195085,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":66220,"kind":"person","name":"Stephenson Pamela","position":1,"cik":"0001767650","reported_name":"Stephenson Pamela","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2020-03-25T16:43:09.000Z","date":"2020-03-25","kind":"sale","acquired":false,"shares":1785,"price":17.6,"value":31416.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to a Rule 10b5-1 arrangement to satisfy tax obligations arising out of the vesting of previously granted restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents 4,465 shares of common stock and 18,750 restricted stock units."}],"balance_after":23215,"source":{"system":"sec-edgar","filing":"0001209191-20-021121","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919120021121/doc4.xml","form_type":"4"}},{"id":3303831,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":66220,"kind":"person","name":"Stephenson Pamela","position":1,"cik":"0001767650","reported_name":"Stephenson Pamela","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2020-01-23T19:42:03.000Z","date":"2020-01-21","kind":"grant","acquired":true,"shares":31500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests as to 25% of the shares on January 21, 2021, with the remainder vesting in equal installments every three months thereafter beginning on April 21, 2021 and ending on January 21, 2024, provided that the vesting of the option may be accelerated, in whole or in part, based on the achievement of certain pre-established company performance criteria, but in no event prior to January 21, 2021."}],"balance_after":31500,"derivative":{"exercise_price":24.67,"expiration_date":"2030-01-20","underlying":"Common Stock","underlying_shares":31500},"source":{"system":"sec-edgar","filing":"0001209191-20-004753","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919120004753/doc4.xml","form_type":"4"}},{"id":3490863,"issuer":{"id":109058,"kind":"organization","name":"Zynerba Pharmaceuticals, Inc.","symbol":"ZYNE"},"owners":[{"id":66220,"kind":"person","name":"Stephenson Pamela","position":1,"cik":"0001767650","reported_name":"Stephenson Pamela","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-06-13T16:22:19.000Z","date":"2019-06-11","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests upon the earlier of (i) June 11, 2020, or (ii) the day before the 2020 annual meeting of stockholders of Zynerba Pharmaceuticals, Inc."}],"balance_after":15000,"derivative":{"exercise_price":13.5,"expiration_date":"2029-06-11","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001192482-19-000288","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1621443/000119248219000288/edgar.xml","form_type":"4"}},{"id":3576293,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":66220,"kind":"person","name":"Stephenson Pamela","position":1,"cik":"0001767650","reported_name":"Stephenson Pamela","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2019-03-27T17:34:13.000Z","date":"2019-03-25","kind":"grant","acquired":true,"shares":37500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests as to 25% of the shares on March 25, 2020 with the remainder vesting in equal installments every three months thereafter, beginning on June 25, 2020 and ending on March 25, 2023."}],"balance_after":37500,"derivative":{"exercise_price":28.76,"expiration_date":"2029-03-24","underlying":"Common Stock","underlying_shares":37500},"source":{"system":"sec-edgar","filing":"0001209191-19-021457","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919119021457/doc4.xml","form_type":"4"}},{"id":3576292,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":66220,"kind":"person","name":"Stephenson Pamela","position":1,"cik":"0001767650","reported_name":"Stephenson Pamela","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2019-03-27T17:34:13.000Z","date":"2019-03-25","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of restricted stock units (\"RSUs\"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest as to 25% of the shares on March 25, 2020 with the remainder vesting in equal installments every three months thereafter, beginning on June 25, 2020 and ending on March 25, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Consists of restricted stock units (\"RSUs\"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest as to 25% of the shares on March 25, 2020 with the remainder vesting in equal installments every three months thereafter, beginning on June 25, 2020 and ending on March 25, 2023."}],"balance_after":25000,"source":{"system":"sec-edgar","filing":"0001209191-19-021457","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919119021457/doc4.xml","form_type":"4"}},{"id":3644610,"issuer":{"id":109058,"kind":"organization","name":"Zynerba Pharmaceuticals, Inc.","symbol":"ZYNE"},"owners":[{"id":66220,"kind":"person","name":"Stephenson Pamela","position":1,"cik":"0001767650","reported_name":"Stephenson Pamela","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-02-20T16:10:43.000Z","date":"2019-02-19","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in three equal installments on February 19, 2020, 2021, and 2022."}],"balance_after":35000,"derivative":{"exercise_price":5.03,"exercise_date":"2020-02-19","expiration_date":"2029-02-19","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001192482-19-000100","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1621443/000119248219000100/edgar.xml","form_type":"4"}}]}